Impact of biologic therapy on the management of moderate to severe psoriasis: a systematic review
Keywords:
Biological Therapy, Psoriasis, Quality Of Life, BiologicsAbstract
Objective: To evaluate the impact of biological therapy in the treatment of moderate to severe psoriasis. Methods: A systematic review based on PubMed data from January 2014 to August 2024. Articles were selected according to study type, intervention, outcomes, and language. Thus, 12 articles were chosen from the 53 that focused on the efficacy and safety of immunotherapies in the treatment of patients with moderate to severe psoriasis. The selection was conducted by more than one researcher, based on the title, abstract, and full text. Results: The main outcomes of the articles were PASI (Psoriasis Area and Severity Index) response rates and patients' quality of life, measured by the DLQI. Among the studies, ixekizumab and brodalumab stood out as highly effective treatments.Discussion: The selected biologics, chosen for their high efficacy, achieved PASI 90-100 and a lower number needed to treat, demonstrating a strong therapeutic capacity by promoting the clearance of psoriatic lesions and significantly improving patients' quality of life. Conclusion: The review highlights that biological therapies, particularly Brodalumab and Ixekizumab, are highly effective for moderate to severe psoriasis, showing rapid responses. Brodalumab is superior in skin clearance, while Ixekizumab provides faster results. Secukinumab and Ustekinumab are also beneficial but less consistent. These therapies represent significant advances, improving clinical outcomes and quality of life, and should be chosen based on patient individuality, efficacy, and safety.
References
- Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019 Mar 23;20(6):1475. doi: 10.3390/ijms20061475. PMID: 30909615; PMCID: PMC6471628.
- Man AM, Orăsan MS, Hoteiuc OA, Olănescu-Vaida-Voevod MC, Mocan T. Inflammation and Psoriasis: A Comprehensive Review. Int J Mol Sci. 2023 Nov 8;24(22):16095. doi: 10.3390/ijms242216095. PMID: 38003284; PMCID: PMC10671208.
- Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, Naldi L, Kinberger M, Afach S, Le Cleach L. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2023 Jul 12;7(7):CD011535. doi: 10.1002/14651858.CD011535.pub6. PMID: 37436070; PMCID: PMC10337265.
- Langley RG, Tsai TF, Flavin S, Song M, Randazzo B, Wasfi Y, Jiang J, Li S, Puig L. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018 Jan;178(1):114-123. doi: 10.1111/bjd.15750. Epub 2017 Oct 10. PMID: 28635018.
- Kokolakis G, Warren RB, Strober B, Blauvelt A, Puig L, Morita A, Gooderham M, Körber A, Vanvoorden V, Wang M, de Cuyper D, Madden C, Nunez Gomez N, Lebwohl M. Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials. Br J Dermatol. 2023 Feb 22;188(3):330-340. doi: 10.1093/bjd/ljac089. PMID: 36751950.
- Chiricozzi A, Balato A, Conrad C, Conti A, Dapavo P, Ferreira P, Gaiani FM, Leite L, Malagoli P, Mendes-Bastos P, Megna M, Messina F, Nidegger A, Odorici G, Panduri S, Piaserico S, Piscitelli L, Prignano F, Ribero S, Valerio J, Torres T. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. J Dermatolog Treat. 2020 Aug;31(5):476-483. doi: 10.1080/09546634.2019.1671577. Epub 2019 Oct 2. PMID: 31557063.
- Leonardi CL, See K, Burge R, Sun Z, Zhang Y, Mallbris L, Garrelts A, Warren RB. Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis. Adv Ther. 2022 May;39(5):2256-2269. doi: 10.1007/s12325-022-02065-w. Epub 2022 Mar 22. PMID: 35316500; PMCID: PMC9056462.
- Sator P, Richter L, Saxinger W, Vasiljevic M, Stingl G. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics. J Eur Acad Dermatol Venereol. 2015 Sep;29(9):1742-9. doi: 10.1111/jdv.12981. Epub 2015 Feb 9. PMID: 25665143.
- Xu G, Xia M, Jiang C, Yu Y, Wang G, Yuan J, Duan X. Comparative efficacy and safety of thirteen biologic therapies for patients with moderate or severe psoriasis: A network meta-analysis. J Pharmacol Sci. 2019 Apr;139(4):289-303. doi: 10.1016/j.jphs.2018.12.006. Epub 2018 Dec 27. PMID: 30922656.
- Papp KA, Gordon KB, Langley RG, Lebwohl MG, Gottlieb AB, Rastogi S, Pillai R, Israel RJ. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018 Aug;179(2):320-328. doi: 10.1111/bjd.16464. Epub 2018 May 23. PMID: 29488226.
- Elewski BE, Puig L, Mordin M, Gilloteau I, Sherif B, Fox T, Gnanasakthy A, Papavassilis C, Strober BE. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. J Dermatolog Treat. 2017 Sep;28(6):492-499. doi: 10.1080/09546634.2017.1294727. Epub 2017 Mar 7. Erratum in: J Dermatolog Treat. 2017 Sep;28(6):571. doi: 10.1080/09546634.2017.1307464. PMID: 28266243.
- Nakagawa H, Niiro H, Ootaki K; Japanese brodalumab study group. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016 Jan;81(1):44-52. doi: 10.1016/j.jdermsci.2015.10.009. Epub 2015 Oct 24. PMID: 26547109.
- Gottlieb AB, Blauvelt A, Thaçi D, Leonardi CL, Poulin Y, Drew J, Peterson L, Arendt C, Burge D, Reich K. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). J Am Acad Dermatol. 2018 Aug;79(2):302-314.e6. doi: 10.1016/j.jaad.2018.04.012. Epub 2018 Apr 13. PMID: 29660421.
- Prinsen CA, Spuls PI, Lindeboom R, Sprangers MA, de Rie MA, de Korte J. The efficacy of a health-related quality-of-life intervention during 48 weeks of biologic treatment of patients with moderate to severe psoriasis: results of a multicentre randomized controlled trial. Br J Dermatol. 2015 Oct;173(4):1091-4. doi: 10.1111/bjd.13906. Epub 2015 Aug 25. PMID: 25975387.
- Parisi, R., Iskandar, I. Y. K., Kontopantelis, E., Augustin, M., Griffiths, C. E. M., & Ashcroft, D. M. (2020). National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ, m1590. doi:10.1136/bmj.m1590
- Puig L. Brodalumab: the first anti-IL-17 receptor agent for psoriasis. Drugs Today (Barc). 2017 May;53(5):283-297. doi: 10.1358/dot.2017.53.5.2613690. PMID: 28650001.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Revista de Divulgação Científica Sena Aires
This work is licensed under a Creative Commons Attribution 4.0 International License.
-
Atribuição — Você deve dar o crédito apropriado, prover um link para a licença e indicar se mudanças foram feitas. Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.
- Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.
